Paxmedica announces first patent allowance for suramin intranasal formulation in the treatment of autism spectrum disorder and other conditions

Boston, ma / accesswire / january 14, 2025 / paxmedica, inc. (otc pink:pxmd), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to announce it has received a notification to grant patent right for chinese invention patent application no: 2020800553323, compositions and methods for treating cognitive, social, or behavioral disabilities and neurodevelopmental disorders, such as those found in individuals impacted by autism. howard weisman, ceo of paxmedica commented, "this is an extraordinary milestone for paxmedica, as this is the first jurisdiction in the world where intellectual property protection of any form of suramin has been approved, since it was first used in humans over 100 years ago.
PXMD Ratings Summary
PXMD Quant Ranking